Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADE and Thalidomide in Newly Diagnosed Multiple Myeloma
NCT00287872Phase 2Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Sep 2004
- Primary completion
- Nov 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in multiple myeloma (MM), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Sep 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00287872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00287872.